WO2019066571A3 - 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 - Google Patents

골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 Download PDF

Info

Publication number
WO2019066571A3
WO2019066571A3 PCT/KR2018/011558 KR2018011558W WO2019066571A3 WO 2019066571 A3 WO2019066571 A3 WO 2019066571A3 KR 2018011558 W KR2018011558 W KR 2018011558W WO 2019066571 A3 WO2019066571 A3 WO 2019066571A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid
derived suppressor
suppressor cells
producing
cells produced
Prior art date
Application number
PCT/KR2018/011558
Other languages
English (en)
French (fr)
Other versions
WO2019066571A2 (ko
Inventor
신성재
김우식
김홍민
권기웅
윤주헌
고원중
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170126379A external-priority patent/KR101944723B1/ko
Priority claimed from KR1020170125990A external-priority patent/KR101946841B1/ko
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to EP18862748.3A priority Critical patent/EP3690030A4/en
Priority to US16/652,349 priority patent/US11806364B2/en
Publication of WO2019066571A2 publication Critical patent/WO2019066571A2/ko
Publication of WO2019066571A3 publication Critical patent/WO2019066571A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

골수 세포에 톨 유사 수용체 작용제(toll-like receptor agonist, TLR agonist) 또는 Ⅰ형 인터페론(type Ⅰ interferon)을 처리하여 골수유래 면역반응 억제세포(myeloid-derived suppressor cells, MDSCs)로 분화를 유도하거나, 이로부터 수지상 세포를 유도하는 방법에 관한 것이다.
PCT/KR2018/011558 2017-09-28 2018-09-28 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 WO2019066571A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP18862748.3A EP3690030A4 (en) 2017-09-28 2018-09-28 METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
US16/652,349 US11806364B2 (en) 2017-09-28 2018-09-28 Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2017-0126379 2017-09-28
KR1020170126379A KR101944723B1 (ko) 2017-09-28 2017-09-28 I형 인터페론을 이용한 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
KR10-2017-0125968 2017-09-28
KR10-2017-0125990 2017-09-28
KR1020170125968 2017-09-28
KR1020170125990A KR101946841B1 (ko) 2017-09-28 2017-09-28 톨 유사 수용체 작용제를 이용한 수지상 세포의 제조방법, 이에 의해 제조된 수지상 세포 및 그 용도

Publications (2)

Publication Number Publication Date
WO2019066571A2 WO2019066571A2 (ko) 2019-04-04
WO2019066571A3 true WO2019066571A3 (ko) 2019-05-23

Family

ID=65902982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011558 WO2019066571A2 (ko) 2017-09-28 2018-09-28 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도

Country Status (3)

Country Link
US (1) US11806364B2 (ko)
EP (1) EP3690030A4 (ko)
WO (1) WO2019066571A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111197029B (zh) * 2020-01-09 2020-11-10 广东省第二人民医院（广东省卫生应急医院） 一种尿酸钠诱导产生髓系抑制性细胞的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030084826A (ko) * 2003-09-30 2003-11-01 국립암센터 동종 종양-관련 항원이 탑재된 수지상세포, 이의 제조방법및 이를 유효성분으로 하는 암 치료용 백신 조성물
KR20150026301A (ko) * 2013-09-02 2015-03-11 인제대학교 산학협력단 골수유래억제세포 분화 유도용 조성물 및 이의 분화 유도방법
KR101734697B1 (ko) * 2015-10-29 2017-05-11 성균관대학교산학협력단 Foxp3를 발현하는 수지상 세포를 포함하는 면역 조절용 약학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP1412390A2 (en) 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
KR101107818B1 (ko) 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
CN101287742B (zh) 2005-10-12 2016-01-06 艾德拉药物股份有限公司 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2009520502A (ja) 2005-12-20 2009-05-28 イデラ ファーマシューティカルズ インコーポレイテッド Ｃｇジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト
JPWO2007119815A1 (ja) 2006-04-14 2009-08-27 協和発酵キリン株式会社 Ｔｏｌｌ様受容体９作動薬
CN101610671A (zh) 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂
AU2008222523A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
JP5721428B2 (ja) 2007-04-27 2015-05-20 バヴァリアン・ノルディック・アクティーゼルスカブ マクロファージ−コロニー刺激因子（ｍ−ｃｓｆ）による樹状細胞発生の誘導
CN101878311A (zh) 2007-08-01 2010-11-03 艾德拉药物股份有限公司 Tlr9的新型合成性激动剂
WO2010062990A1 (en) 2008-11-26 2010-06-03 Mount Sinai School Of Medicine Of New York University In vitro generation of myeloid derived suppressor cells
AU2010208250A1 (en) 2009-01-30 2011-08-04 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR 9
EP2515919A2 (en) * 2009-12-22 2012-10-31 Mount Sinai School of Medicine Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CN106459058B (zh) 2014-05-01 2019-07-05 诺华股份有限公司 作为toll-样受体7激动剂的化合物和组合物
CR20160512A (es) 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
KR101894428B1 (ko) 2015-07-20 2018-09-03 가톨릭대학교 산학협력단 제대혈 ｃｄ３４ 양성 세포에서 골수유래억제세포로의 분화 유도 및 증식 방법, 및 상기 골수유래억제세포의 용도
KR101803149B1 (ko) 2015-09-11 2017-11-29 충북대학교 산학협력단 미노사이클린을 이용하여 제조된 면역관용 수지상 세포 및 이의 제조방법
KR101913353B1 (ko) 2016-03-07 2018-10-31 연세대학교 산학협력단 면역 억제 능력을 가지는 수지상세포-유사 세포 및 그 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030084826A (ko) * 2003-09-30 2003-11-01 국립암센터 동종 종양-관련 항원이 탑재된 수지상세포, 이의 제조방법및 이를 유효성분으로 하는 암 치료용 백신 조성물
KR20150026301A (ko) * 2013-09-02 2015-03-11 인제대학교 산학협력단 골수유래억제세포 분화 유도용 조성물 및 이의 분화 유도방법
KR101734697B1 (ko) * 2015-10-29 2017-05-11 성균관대학교산학협력단 Foxp3를 발현하는 수지상 세포를 포함하는 면역 조절용 약학적 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MILLRUD, C. R. ET AL.: "On the Origin of Myeloid-derived Suppressor Cells", ONCOTARGET, vol. 8, no. 2, 27 September 2016 (2016-09-27) - January 2017 (2017-01-01), pages 3649 - 3665, XP055613915 *
TALEB, K. ET AL.: "Chronic Type I IFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells", THE JOURNAL OF IMMUNOLOGY, vol. 198, no. 3, 21 December 2016 (2016-12-21) - 1 February 2017 (2017-02-01), pages 1156 - 1163, XP055613918 *
YOUN, J. 1. ET AL.: "The Biology of Myeloid-derived Suppressor Cells: The Blessing and the Curse of Morphological and Functional Heterogeneity", EUR J. IMMUNOL, vol. 40, 2010, pages 2969 - 2975, XP055151334, DOI: doi:10.1002/eji.201040895 *

Also Published As

Publication number Publication date
EP3690030A4 (en) 2021-06-23
US11806364B2 (en) 2023-11-07
WO2019066571A2 (ko) 2019-04-04
EP3690030A2 (en) 2020-08-05
US20200316117A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
MX2016005739A (es) Metodo, dispositivo y sistema para actualizar aplicaciones.
NZ723336A (en) Methods and compositions for isolating exosomes
SG10201808165YA (en) Sample analysis for mass cytometry
MX2018002293A (es) Sistemas y métodos para las llamadas variantes de alta precisión.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
NZ715815A (en) High-stability t-cell receptor and preparation method and application thereof
BR112016020517A2 (pt) método de produção de lipídeo através da utilização de ss-cetoacil-acp sintase
MY190347A (en) Production method for insoluble recombinant protein aggregate
PH12017502120B1 (en) A method and an apparatus for forming a lignin fraction, a lignin composition and its use
MX2024001617A (es) Composiciones biofarmaceuticas.
MX2020002649A (es) Metodos para hacer y usar endoxifeno.
MX2021007245A (es) Microorganismos para la produccion de putrescina u ornitina y procedimiento para la produccion de putrescina u ornitina usando los mismos.
WO2020128870A3 (en) Methods of producing heterodimeric antibodies
MX2019015447A (es) Metodo para separar monomero no reaccionado de solucion de mezcla que incluye monomero no reaccionado.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2019066571A3 (ko) 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
MX2015015953A (es) Composicion que comprende una combinacion de un polimero acrilico y una silicona amino.
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2019007978A (es) Mezcla para la fabricacion de un producto ceramico refractario no moldeado, procedimiento para la fabricacion de un producto ceramico refractario no moldeado asi como un producto ceramico refractario no moldeado fabricado por ello.
MX2022005134A (es) Metodos para producir celulas del epitelio pigmentario retiniano.
MX2019000747A (es) Toner de seguridad y proceso para usarlo.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
AU2018253555A1 (en) Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18862748

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018862748

Country of ref document: EP

Effective date: 20200428